93 related articles for article (PubMed ID: 23638744)
1. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Muselaers S; Mulders P; Oosterwijk E; Oyen W; Boerman O
Immunotherapy; 2013 May; 5(5):489-95. PubMed ID: 23638744
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
3. G250: a carbonic anhydrase IX monoclonal antibody.
Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Leppert JT; Lam JS; Pantuck AJ; Figlin RA; Belldegrun AS
BJU Int; 2005 Aug; 96(3):281-5. PubMed ID: 16042714
[TBL] [Abstract][Full Text] [Related]
5. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
6. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
7. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Muselaers CH; Boers-Sonderen MJ; van Oostenbrugge TJ; Boerman OC; Desar IM; Stillebroer AB; Mulder SF; van Herpen CM; Langenhuijsen JF; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2016 May; 69(5):767-70. PubMed ID: 26706103
[TBL] [Abstract][Full Text] [Related]
8. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Brouwers AH; Mulders PF; Oyen WJ
J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
[No Abstract] [Full Text] [Related]
10. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Lamers CH; Sleijfer S; Vulto AG; Kruit WH; Kliffen M; Debets R; Gratama JW; Stoter G; Oosterwijk E
J Clin Oncol; 2006 May; 24(13):e20-2. PubMed ID: 16648493
[No Abstract] [Full Text] [Related]
12. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Zisman A; Pantuck AJ; Bui MH; Said JW; Caliliw RR; Rao N; Shintaku P; Berger F; Gambhir SS; Belldegrun AS
Cancer Res; 2003 Aug; 63(16):4952-9. PubMed ID: 12941820
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Tickoo SK; Alden D; Olgac S; Fine SW; Russo P; Kondagunta GV; Motzer RJ; Reuter VE
J Urol; 2007 Apr; 177(4):1258-63. PubMed ID: 17382701
[TBL] [Abstract][Full Text] [Related]
14. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
[TBL] [Abstract][Full Text] [Related]
15. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis.
Dorai T; Sawczuk I; Pastorek J; Wiernik PH; Dutcher JP
Cancer Invest; 2006 Dec; 24(8):754-79. PubMed ID: 17162558
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK; Nordsmark M; Donskov F; Marcussen N; von der Maase H
BJU Int; 2008 Jun; 101 Suppl 4():41-4. PubMed ID: 18430123
[No Abstract] [Full Text] [Related]
19. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
20. Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.
Nat Rev Drug Discov; 2011 Jul; 10(7):482. PubMed ID: 21720396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
